Telix Pharmaceuticals (Telix Pharmaceuticals) Change In Receivables : $0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Change In Receivables?

Telix Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2023 was $0.0 Mil. It means Telix Pharmaceuticals's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Telix Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $0.0 Mil. It means Telix Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Telix Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2023 was $43.4 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Telix Pharmaceuticals's Days Sales Outstanding for the six months ended in Dec. 2023 was 42.47.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Telix Pharmaceuticals's liquidation value for the six months ended in Dec. 2023 was $-46.1 Mil.

Telix Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Telix Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Change In Receivables Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Telix Pharmaceuticals Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial								-	-	-	-	-

Telix Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

Telix Pharmaceuticals (OTCPK:TLPPF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Telix Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	43.358	/	186.311	*	91
=	42.47

2. In Ben Graham's calculation of liquidation value, Telix Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Telix Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	82.488	-	166.928	+	0.75 * 43.358	+	0.5 * 11.586
=	-46.1

Telix Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

TLX:Australia

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.